Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences
29 mars 2022 10h56 HE
|
Cytovia Therapeutics
AVENTURA, Fla. and NATICK, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Multispecific Antibodies at 2022 AACR Annual Meeting
16 mars 2022 08h00 HE
|
Cytovia Therapeutics
AVENTURA, Fla. and NATICK, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
12 oct. 2021 12h24 HE
|
Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline
13 sept. 2021 10h08 HE
|
Cytovia Therapeutics
Cytovia eligible for up to $400 million in licensing milestones for Greater China rightsCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma AVENTURA,...
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer
22 juin 2021 08h55 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
15 juin 2021 13h21 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences
14 mai 2021 10h58 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics Expands Leadership Team
13 mai 2021 09h48 HE
|
Cytovia Therapeutics
Jason Aryeh elected to Board of DirectorsElizabeth Schwarzbach, PhD and Boris Reznik, PhD join Strategic Advisory BoardElysa Mantel appointed as Vice President, General Counsel and Corporate Secretary...
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
28 avr. 2021 13h16 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
12 avr. 2021 11h11 HE
|
Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...